Acceptable plasma concentrations of raltegravir and etravirine when administered by gastrostomy tube in a patient with advanced multidrug-resistant human immunodeficiency virus infection

Pharmacotherapy

Volumn 32, Issue 2, 2012, Pages 142-147

  Sandkovsky, Uriel ^a   Swindells, Susan ^a   Moore, Ryan ^c   Acosta, Edward P ^d   Fletcher, Courtney V ^b,c  

^a Department of Internal Medicine   (United States)

^b Antiviral Pharmacology Laboratory   (United States)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Emtricitabine tenofovir; Etravirine; Gastrostomy tube; Pharmacokinetics; Plasma concentrations; Raltegravir

Indexed keywords

EMTRICITABINE; ETRAVIRINE; RALTEGRAVIR; TENOFOVIR;

ADULT; ARTICLE; CASE REPORT; CONTROLLED STUDY; DRUG ABSORPTION; DRUG ADMINISTRATION ROUTE; DRUG BLOOD LEVEL; DRUG RESPONSE; ESOPHAGUS PERFORATION; HEPATITIS B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MAXIMUM PLASMA CONCENTRATION; MIXED INFECTION; MORNING DOSAGE; MULTIDRUG RESISTANCE; OUTCOME ASSESSMENT; STOMACH TUBE;

DRUG INTERACTIONS; DRUG RESISTANCE, MULTIPLE; DRUG THERAPY, COMBINATION; GASTROSTOMY; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PYRIDAZINES; PYRROLIDINONES;

EID: 84864597972     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1002/PHAR.1015     Document Type: Article

References (25)

1. Zolopa A, Andersen J, Powderly W, et al. Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial. PLoS One 2009;4:e5575.
2. National Institutes of Health, Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents, January 10, 2011. Available from http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed June 10, 2011.
3. Gilead Sciences, Inc. Viread (tenofovir disoproxil fumarate) package insert. Foster City, CA; 2010.
4. Scholler-Gyure M, Covitz M, Kakuda TN, et al. Bioavailability of the 100 mg etravirine tablet dispersed in water and of the 25 mg pediatric tablet formulation [abstract]. Presented at the 21st annual conference of the Association of Nurses in AIDS Care; Tucson, AZ, November 6-8, 2008.
5. National Institutes of Health, Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the use of antiretroviral agents in pediatric HIV Infection. Available from http://aidsinfo.nih.gov/ContentFiles/PediatricGuidelines.pdf. Accessed June 13, 2011.
6. Kaul S, Ji P, Lu M, Nguyen KL, Shangguan T, Grasela D. Bioavailability in healthy adults of efavirenz capsule contents mixed with a small amount of food. Am J Health Syst Pharm 2010;67:217-22.
7. Bristol-Myers Squibb. An expanded access study of oral liquid efavirenz in the treatment of children with HIV infection. ClinicalTrials. gov. Bethesda, MD: National Library of Medicine. Available from http://clinicaltrials.gov/ct2/ show/NCT00162227. Accessed June 7, 2011.
8. Diep H BB, Capparelli EV, Rossi SS, et al. Pharmacokinetics of Lopinavir/Ritonavir Crushed vs Whole Tablets in Children [abstract 877]. Presented at the 17th conference on retroviruses and opportunistic infections, San Francisco, CA, February 16-19, 2010.
9. Merck and Co. Inc. Isentress (raltegravir) package insert. Whitehouse Station, NJ; 2008.
10. Answers.com. Raltegravir, 2011; Available from http://www. answers.com/topic/raltegravir. Accessed May 26, 2011.
11. European Medicines Agency. Isentress summary of product characteristics. Available from http://www.ema.europa.eu/docs/en-GB/document-library/EPARProduct- Information/human/000860/WC500037405.pdf. Accessed May 26, 2011.
12. Markowitz M, Morales-Ramirez JO, Nguyen BY, et al. Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals. J Acquir Immune Defic Syndr 2006;43:509-15.
13. Zhu L, Butterton J, Persson A, et al. Pharmacokinetics and safety of twice-daily atazanavir 300 mg and raltegravir 400 mg in healthy individuals. Antivir Ther 2010;15:1107-14.
14. Kakuda TN, Wade JR, Snoeck E, et al. Pharmacokinetics and pharmacodynamics of the non-nucleoside reverse-transcriptase inhibitor etravirine in treatment-experienced HIV-1-infected patients. Clin Pharmacol Ther 2010;88:695-703.
15. Scholler-Gyure M, Kakuda TN, Raoof A, De Smedt G, Hoetelmans RM. Clinical pharmacokinetics and pharmacodynamics of etravirine. Clin Pharmacokinet 2009;48:561-74.
16. German P, Warren D, West S, Hui J, Kearney BP. Pharmacokinetics and bioavailability of an integrase and novel pharmacoenhancer- containing single-tablet fixed-dose combination regimen for the treatment of HIV. J Acquir Immune Defic Syndr 2010;55:323-9.
17. Kiser JJ, Carten ML, Aquilante CL, et al. The effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIVinfected patients. Clin Pharmacol Ther 2008;83:265-72.
18. Brainard DM, Friedman EJ, Jin B, et al. Effect of low-, moderate-, and high-fat meals on raltegravir pharmacokinetics. J Clin Pharmacol 2011;51:422-7.
19. Brainard DM, Wenning LA, Stone JA, Wagner JA, Iwamoto M. Clinical pharmacology profile of raltegravir, an HIV-1 integrase strand transfer inhibitor. J Clin Pharmacol 2011;51:1376-402.
20. Iwamoto M, Wenning LA, Nguyen BY, et al. Effects of omeprazole on plasma levels of raltegravir. Clin Infect Dis 2009;48:489-92.
21. Anderson MS, Kakuda TN, Hanley W, et al. Minimal pharmacokinetic interaction between the human immunodeficiency virus nonnucleoside reverse transcriptase inhibitor etravirine and the integrase inhibitor raltegravir in healthy subjects. Antimicrob Agents Chemother 2008;52:4228-32.
22. Wenning LA, Friedman EJ, Kost JT, et al. Lack of a significant drug interaction between raltegravir and tenofovir. Antimicrob Agents Chemother 2008;52:3253-8.
23. Tibotec Pharmaceuticals. Intelence (etravirine) package insert. Raritan, NJ; 2010.
24. Gilead Sciences Inc. Truvada (emtricitabine-tenofovir disoproxil fumarate) package Insert. Foster City, CA; 2009.
25. Parks DA, Jennings HC, Taylor C, Pakes GE, Acosta EP. Steady-state amprenavir, tenofovir, and emtricitabine pharmacokinetics before and after reducing ritonavir boosting of a fosamprenavir-tenofovir-emtricitabine regimen from 200 mg to 100 mg once daily (TELEX II). HIV Clin Trials 2009;10:160-7.